title: Therapy of patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatin.
abstract: Thirty-four women with metastatic breast cancer were treated at the National Cancer Institute of the National Institutes of Health, with a regimen of leucovorin (L), 500 mg/m2 i.v. over 30 min, followed in 1 h by 5-fluorouracil (5-FU), 375 mg/m2 i.v. bolus on days 1-5, and carboplatin (CBDCA), 50-100 mg/m2 i.v. bolus on days 2-4, every 28 days. All patients had received previous combination chemotherapy with at least one regimen (29 patients with 5-FU-containing regimens). CBDCA, 100 mg/m2 on days 2-4, resulted in grade 4 neutropenia in 10 out of 11 patients associated with sepsis in all 10 patients. CBDCA, 75 mg/m2 (seven patients) and 50 mg/m2 (15 patients), resulted in grade 4 neutropenia in six and eight patients, and neutropenic sepsis in five and two cases, respectively. Grade 4 thrombocytopenia occurred in 10, five and two patients receiving 100, 75 and 50 mg/m2 of CBDCA, respectively. Other toxicities included grade 3/4 mucositis in 18 patients and grade 3/4 diarrhea in 10 patients. Twenty nine patients were evaluable for response, with one pathologic complete response (3%), two partial responses (6%), 18 stable disease (53%) and eight (24%) progressive disease. Sites of response included bone, viscera and soft tissue. The median time from entry on study to progression, for responders, was 15 months. When platinum-DNA adduct formation in peripheral white blood cells was analyzed in 27 patients at 24 h after drug administration, a significant correlation between adduct level and CBDCA cumulative dose was found.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: National Cancer Institute, National Institute of Health, Bethesda, MD 20892.
authors.forename: L H
authors.initials: LH
authors.lastname: Pai
authors.forename: S M
authors.initials: SM
authors.lastname: Swain
authors.forename: D J
authors.initials: DJ
authors.lastname: Venzon
authors.forename: E
authors.initials: E
authors.lastname: Reed
authors.forename: M C
authors.initials: MC
authors.lastname: Poirier
authors.forename: S
authors.initials: S
authors.lastname: Gupta-Burt
authors.forename: A M
authors.initials: AM
authors.lastname: Denicoff
authors.forename: C J
authors.initials: CJ
authors.lastname: Allegra
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000556:secondary*; D016190:Carboplatin / Q000008:administration & dosage / Q000097:blood; D004273:DNA, Neoplasm / Q000097:blood / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008875:Middle Aged
chemical_list: D004273:DNA, Neoplasm; D016190:Carboplatin; D002955:Leucovorin; D005472:Fluorouracil